MedTrace Logo

Effects of RAS in Stroke

NCT06830785 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-06-25

No results posted yet for this study

Summary

The goal of this study is to to examine whether rhythmic auditory stimulation improved movement speed, movement function of executing activities of daily living, and movement recovery of the affected upper limb, as well as quality of life in stroke patients. The main questions it aims to answer are:

* Does rhythmic auditory stimulation improve movement speed in stroke patients?
* Does rhythmic auditory stimulation improve movement function of executing activities of daily living in stroke patients?
* Does rhythmic auditory stimulation improve movement recovery of the affected upper limb in stroke patients?
* Does rhythmic auditory stimulation improve quality of life in stroke patients?

Researchers will compare movement training with the aid of rhythmic auditory stimulation to movement training without the aid of rhythmic auditory stimulation to see if rhythmic auditory stimulation works to improve movement speed, movement function of executing activities of daily living, and movement recovery of the affected upper limb, as well as quality of life in stroke patients.

Participants will:

* Undergo movement tests and fill out questionnaires before and after the movement training program
* Receive movement training for 40 minutes per session and three sessions per week for a total of 24 sessions

Conditions

Interventions

BEHAVIORAL

rhythmic auditory stimulation incorporated in upper-limb movement training

Rhythmic auditory stimulation will be metronome beat sound with different tempi and will be incorporated in upper-limb movement training, which will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.

BEHAVIORAL

Upper-limb movement training

Upper-limb movement training will last for 40 minutes per session, three sessions per week, and a total of 24 sessions.

Sponsors & Collaborators

  • Shu-Mei Wang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06830785 on ClinicalTrials.gov